Phenoxodiol trials: focus on ovarian not prostate cancer
Phenoxodiol’s fast track status at FDA generates a lot on interest among men with advanced prostate cancer. But despite evidence that Phenoxodiol delays progression in hormone refractory prostate cancer, is the fast track to FDA approval petering out?
(full story…)